Join to View Full Profile
361 Old Belgrade RdAlfond Cancer CenterAugusta, ME 04330
Phone+1 207-621-6100
Fax+1 207-621-6102
Dr. Hertler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1985 - 1988
University of MichiganResidency, Internal Medicine, 1982 - 1984
University of Michigan Medical SchoolClass of 1982
Certifications & Licensure
ME State Medical License 1996 - 2026
MO State Medical License 2018 - 2026
NH State Medical License 2020 - 2026
KY State Medical License 2019 - 2025
NJ State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
- Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain Start of enrollment: 2011 May 01
Publications & Presentations
PubMed
- 9 citationsUtilization of Clinical Pathways Can Reduce Drug Spend Within the Oncology Care Model.Andrew Allan Hertler, Sang Chau, Rani Khetarpal, Ed Bassin, Jeff Dang
JCO Oncology Practice. 2020-03-20 - 18 citationsUsing Big Data and Predictive Analytics to Determine Patient Risk in Oncology.Ravi B. Parikh, Andrew Gdowski, Debra Patt, Andrew Hertler, Craig H. Mermel
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2019-05-17
Press Mentions
Year in Review – Endometrial CancerNovember 11th, 2024- New Century Health Partner Cancer Care Specialists of Illinois Earns $3.6 Million from Medicare Through Federal Oncology Care ModelMarch 10th, 2022
- FDA Panel Largely Backs Speedy Cancer Drug Approvals, Forcing Tough Choice for AgencyApril 30th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
